SCHEMBL1178968

SCHEMBL1178968

O=C(NCCCn1ccnc1)c1cc(-c2cccs2)on1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 1.00
LMNA P02545 9/20 1.00
NPC1 O15118 6/20 1.00
KDM4E B2RXH2 2/20 1.00
NFKB1 P19838 1/20 1.00
NFKB2 Q00653 1/20 1.00
RELA Q04206 1/20 1.00
SMN1; SMN2 Q16637 3/20 0.73
HTT P42858 1/20 0.73
HIF1A Q16665 1/20 0.73
ALDH1A1 P00352 1/20 0.67
GAA P10253 1/20 0.67
GLA P06280 1/20 0.65
HSD17B10 Q99714 1/20 0.65
MAPK1 P28482 1/20 0.62
HPGD P15428 1/20 0.59
TSHR P16473 1/20 0.58
NAMPT P43490 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1179007 0.94 RAB9A (0.88) RAB9ALMNANPC1KDM4ENFKB1
SCHEMBL1474399 0.85 LMNA (0.86) RAB9ALMNANPC1KDM4ENFKB1
SCHEMBL15189911 0.84 LMNA (0.73) RAB9ALMNANPC1KDM4ENFKB1
SCHEMBL1179277 0.84 LMNA (1.00) RAB9ALMNANPC1KDM4ENFKB1
SCHEMBL1475703 0.83 LMNA (0.72) RAB9ALMNANPC1KDM4ENFKB1
SCHEMBL1177953 0.83 LMNA (0.72) RAB9ALMNANPC1KDM4ENFKB1
SCHEMBL27176262 0.82 LMNA (0.70) RAB9ALMNANPC1KDM4ENFKB1
SCHEMBL1178443 0.82 RAB9A (0.74) RAB9ALMNANPC1KDM4ENFKB1
SCHEMBL27176254 0.82 RAB9A (0.70) RAB9ALMNANPC1KDM4ENFKB1
SCHEMBL1474961 0.82 LMNA (0.76) RAB9ALMNANPC1KDM4ENFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114004486-B Rail transit passenger flow scheduling system, method, storage medium and equipment 广州广电运通智能科技有限公司 2025-03-07 CN claimed
CN-114004486-A Rail transit passenger flow scheduling system, method, storage medium and equipment 广州广电运通智能科技有限公司 2022-02-01 CN claimed
US-8518978-B2 Pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-08-27 US claimed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US claimed
CN-114004486-B Rail transit passenger flow scheduling system, method, storage medium and equipment 广州广电运通智能科技有限公司 2025-03-07 CN disclosed
US-20240294876-A1 METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF UNIV SOUTHERN CALIFORNIA (US) 2024-09-05 US disclosed
CN-114222974-B Estimating processing impact of user interface changes using state space models 微软技术许可有限责任公司 2024-04-19 CN disclosed
EP-4341386-A2 METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF University of Southern California (US) 2024-03-27 EP disclosed
CN-117751182-A Method for amplifying human granulocyte-macrophage progenitor cells and application thereof 南加利福尼亚大学 2024-03-22 CN disclosed
CN-114731323-B Detection method and device for Multiple Input Multiple Output (MIMO) system 华为技术有限公司 2023-09-12 CN disclosed
EP-4218748-A2 BMP-MIMETICS Christian-Albrechts-Universität zu Kiel (DE) 2023-08-02 EP disclosed
WO-2022245977-A2 METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2022-11-24 WO disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20110028506-A1 Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-02-03 US disclosed
US-20110028506-A1 Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-02-03 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028506-A1 Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives PTGIR, GPR119, PTGIS RAB9A 2717/4885LMNA 2579/4885NPC1 1805/4885
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 RAB9A 2013/4885LMNA 2934/4885NPC1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.